[go: up one dir, main page]

AR108753A1 - Uso de insulina para promover el vaciamiento gástrico, composición y kit - Google Patents

Uso de insulina para promover el vaciamiento gástrico, composición y kit

Info

Publication number
AR108753A1
AR108753A1 ARP170100743A ARP170100743A AR108753A1 AR 108753 A1 AR108753 A1 AR 108753A1 AR P170100743 A ARP170100743 A AR P170100743A AR P170100743 A ARP170100743 A AR P170100743A AR 108753 A1 AR108753 A1 AR 108753A1
Authority
AR
Argentina
Prior art keywords
insulin
gastric emptying
composition
kit
promote gastric
Prior art date
Application number
ARP170100743A
Other languages
English (en)
Inventor
Tal Atarot
Michal Olshansky
Original Assignee
Nutrinia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrinia Ltd filed Critical Nutrinia Ltd
Publication of AR108753A1 publication Critical patent/AR108753A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicación 1: Un método para promover el vaciamiento gástrico en un sujeto que lo necesite, que comprende la etapa de administrar por vía enteral una cantidad efectiva de insulina o una composición que la comprende al sujeto, promoviendo con ello el vaciamiento gástrico en dicho sujeto. Reivindicación 14: El procedimiento de la reivindicación 1, en el que la insulina se encapsula en una matriz de encapsulación. Reivindicación 15: El método de la reivindicación 14, en el que la matriz de encapsulación comprende maltodextrina.
ARP170100743A 2016-03-24 2017-03-27 Uso de insulina para promover el vaciamiento gástrico, composición y kit AR108753A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662312473P 2016-03-24 2016-03-24

Publications (1)

Publication Number Publication Date
AR108753A1 true AR108753A1 (es) 2018-09-26

Family

ID=59900798

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100743A AR108753A1 (es) 2016-03-24 2017-03-27 Uso de insulina para promover el vaciamiento gástrico, composición y kit

Country Status (20)

Country Link
US (1) US10046032B2 (es)
EP (1) EP3432861B1 (es)
JP (1) JP7102347B2 (es)
KR (1) KR20180123114A (es)
CN (1) CN109152733A (es)
AR (1) AR108753A1 (es)
AU (1) AU2017237164A1 (es)
BR (1) BR112018069444A2 (es)
CA (1) CA3018215C (es)
ES (1) ES2957891T3 (es)
HR (1) HRP20230972T1 (es)
HU (1) HUE062950T2 (es)
IL (1) IL261898A (es)
MX (1) MX2018011512A (es)
PL (1) PL3432861T3 (es)
RS (1) RS64623B1 (es)
RU (1) RU2018133604A (es)
SG (1) SG11201808154XA (es)
SM (1) SMT202300323T1 (es)
WO (1) WO2017165789A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7102347B2 (ja) 2016-03-24 2022-07-19 エルガン ファーマ リミテッド 胃内容排出を増進させるインスリンの使用
EP4322989A4 (en) * 2021-04-11 2025-03-05 Elgan Pharma Ltd. INSULIN FORMULATIONS AND METHODS OF USE IN PREMATURE INFANTS

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
ATE106242T1 (de) 1986-08-28 1994-06-15 Enzacor Pty Ltd Mikrogranuläre zubereitung zur verabreichung biologisch aktiver stoffe in den eingeweideregionen von tieren.
FR2606597B1 (fr) 1986-11-17 1989-01-27 Rhone Poulenc Sante Nouvelle composition pour l'alimentation des ruminants contenant une substance biologiquement active et sa preparation
US4944944A (en) 1987-11-19 1990-07-31 Oklahoma Medical Research Foundation Dietary compositions and methods using bile salt-activated lipase
US5013569A (en) 1990-05-21 1991-05-07 Century Laboratories, Inc. Infant formula
US5418010A (en) 1990-10-05 1995-05-23 Griffith Laboratories Worldwide, Inc. Microencapsulation process
DE4100920A1 (de) 1991-01-15 1992-07-16 Degussa Wirkstoffzubereitung zur oralen verabreichung an wiederkaeuer
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5360614A (en) 1993-04-26 1994-11-01 The Estee Corporation Method of controlling the release of carbohydrates by encapsulation and composition therefor
US5405637A (en) 1993-06-30 1995-04-11 Bristol-Myers Squibb Company Milk protein partial hydrolysate and infant formula containing same
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
ES2164205T3 (es) 1995-06-29 2002-02-16 Nestle Sa Procedimiento de encapsulacion de un material de nucleo con un polimero, por un tratamiento de alta presion.
JPH10155428A (ja) 1996-12-04 1998-06-16 Shida Kanzume Kk 毛づや改善剤及び毛づやの改善方法、並びに健康食品
CN1660065A (zh) 1997-03-27 2005-08-31 布里斯托尔-迈尔斯斯奎布公司 二十二碳六烯酸和花生四烯酸促进不足月婴儿生长的用途
JPH119196A (ja) 1997-06-24 1999-01-19 Meiji Seika Kaisha Ltd キトサンによる家畜の損耗防止の方法
ATE246039T1 (de) 1997-09-09 2003-08-15 Select Release L C Beschichtete teilchen, methode zu ihrer herstellung und verwendung
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
WO1999062558A1 (en) 1998-06-05 1999-12-09 Technion Research And Development Foundation Ltd. Insulin supplemented infant formula
US6399090B1 (en) 1998-06-05 2002-06-04 Insotech Ltd. Insulin supplemented infant formula
JP2000050793A (ja) 1998-08-07 2000-02-22 Meiji Milk Prod Co Ltd 人工乳組成物
JP2000116320A (ja) 1998-10-13 2000-04-25 Bingu Gure:Kk 乳酸菌カプセル入りヨーグルト及びその製造方法
GB2345836A (en) 1999-01-25 2000-07-26 Charleville Res Animal milk replacer
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6548043B1 (en) 1999-08-03 2003-04-15 Metabolic Solutions, Inc. Measurement of gastric emptying
MXPA02010322A (es) 2000-04-19 2004-09-10 Univ Johns Hopkins Metodos para la prevencion y tratamiento de trastornos gastrointestinales.
ES2262667T3 (es) 2000-05-25 2006-12-01 Societe Des Produits Nestle S.A. Probioticos nuevos para aplicaciones en alimento para animales de compañia.
JP2002209513A (ja) 2000-12-15 2002-07-30 Bingu-Gure:Kk 栄養成分を含有する多数のカプセル入り強化牛乳
ATE290324T1 (de) 2000-12-15 2005-03-15 Quest Int Eine feuchtigkeit- und sauerstoff-stabile zusammensetzung und verfahren zur herstellung
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
EA007301B1 (ru) 2001-05-14 2006-08-25 Василий Петрович Андрейчук Биологически активная добавка к пище и биологически активная кормовая добавка для профилактики йодной недостаточности и оптимизации йодного обмена, пищевой и кормовой продукты, содержащие указанные добавки
CA2449202A1 (en) 2001-05-23 2002-11-28 Institut National De La Recherche Scientifique Biocompatible compositions as carriers or excipients for pharmaceutical and nutraceutical formulations and for food protection
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US6951655B2 (en) 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
US20030175403A1 (en) 2002-03-14 2003-09-18 Gurin Michael H. Potentiated bioactive additives and method of use
US20030175382A1 (en) 2002-03-14 2003-09-18 Dally Vernetta L. Heat released encapsulated yeast
WO2004003188A2 (en) 2002-07-01 2004-01-08 Novozymes A/S Stabilization of granules
US6835397B2 (en) 2002-12-23 2004-12-28 Balchem Corporation Controlled release encapsulated bioactive substances
US8877232B2 (en) 2003-06-20 2014-11-04 Nutrinia Ltd. Bioactive compounds protection method and compositions containing the same
EP1758464A4 (en) 2004-05-24 2012-10-24 Nutrinia Ltd NUTRITIONAL FOOD AND SUPPLEMENT, ITS COMPOSITION, PROCESSING AND METHOD FOR ITS USE
WO2005117951A1 (en) 2004-06-02 2005-12-15 Technion Research & Development Foundation Ltd. Methods and formulations for increasing intestinal function
GB0502795D0 (en) 2005-02-10 2005-03-16 Univ Cambridge Tech Treatment of very low birthweight (vlbw) infants
JP5222727B2 (ja) 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド タンパク質を経口投与するための方法及び組成物
EP2150272B1 (en) 2007-06-07 2013-08-14 Nutrinia Ltd. Means and methods for enhancing weight gain in poultry
US7943733B2 (en) 2007-12-20 2011-05-17 University Of Southern California Spacers to increase the expression of recombinant fusion proteins
WO2012052060A1 (en) 2010-10-21 2012-04-26 Swedish Orphan Biovitrum Ab (Publ) Method to increase the growth velocity of human infants
EP2520298A1 (en) 2011-05-03 2012-11-07 Assistance Publique, Hopitaux De Paris Pharmaceutical composition comprising sulfonylureas (glibenclamide) or meglitinides for use for treating hyperglycaemia or for promoting growth of a premature infant
CN113080448A (zh) 2012-04-18 2021-07-09 爱儿安制药有限公司 婴儿的生长促进
US20150209412A1 (en) 2012-05-31 2015-07-30 Nutrinia Ltd. Insulin-containing infant formula
JP7102347B2 (ja) 2016-03-24 2022-07-19 エルガン ファーマ リミテッド 胃内容排出を増進させるインスリンの使用

Also Published As

Publication number Publication date
KR20180123114A (ko) 2018-11-14
MX2018011512A (es) 2019-02-07
CA3018215C (en) 2023-10-03
EP3432861A4 (en) 2019-10-23
JP7102347B2 (ja) 2022-07-19
EP3432861C0 (en) 2023-07-12
RU2018133604A (ru) 2020-04-24
HUE062950T2 (hu) 2023-12-28
JP2019509317A (ja) 2019-04-04
RS64623B1 (sr) 2023-10-31
SG11201808154XA (en) 2018-10-30
PL3432861T3 (pl) 2023-12-18
ES2957891T3 (es) 2024-01-29
CN109152733A (zh) 2019-01-04
NZ746622A (en) 2024-12-20
AU2017237164A1 (en) 2018-10-11
WO2017165789A1 (en) 2017-09-28
EP3432861B1 (en) 2023-07-12
CA3018215A1 (en) 2017-09-28
SMT202300323T1 (it) 2023-11-13
BR112018069444A2 (pt) 2019-10-08
HRP20230972T1 (hr) 2023-12-08
EP3432861A1 (en) 2019-01-30
US20170319663A1 (en) 2017-11-09
US10046032B2 (en) 2018-08-14
IL261898A (en) 2018-10-31

Similar Documents

Publication Publication Date Title
MX2020006964A (es) Composicion farmaceutica que comprende un cannabinoide.
CL2018001646A1 (es) Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma. (divisional solicitud 201602105)
PE20211069A1 (es) Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina
CL2016002023A1 (es) “compuestos derivados de benzoato-4-(amidoamino)- sustituido con un grupo oxazol dicarboxilico, inhibidores de enteropeptidasa; composición farmacéutica que los comprende; y su uso en el tratamiento de obesidad y diabetes mellitus”. pct
PE20160781A1 (es) Formulaciones de insulina de accion prolongada
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
MX367241B (es) Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer.
BR112017000313A2 (pt) sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
PE20181095A1 (es) Envase blister
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
CL2018000963A1 (es) Cosmética que tiene bacterias probióticas
CL2015003634A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2016000950A1 (es) Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2.
UY36561A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2015002914A1 (es) Tratamiento de la diabetes mellitus mediante formulaciones de la insulinas de acción prolongada
CL2015002253A1 (es) Composiciones farmacéuticas para el tratamiento de la helicobacter pylori.
UY35905A (es) Inhibidores del transporte de glucosa
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
AR108753A1 (es) Uso de insulina para promover el vaciamiento gástrico, composición y kit
PE20211864A1 (es) Uso de lecitinas como biocida contra artropodos
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.

Legal Events

Date Code Title Description
FC Refusal